anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided is an application of doxorubicin hydrochloride in the preparation of an inhibitor of an anti-apoptotic protein Mcl-1. The present invention specifically relates to use of doxorubicin hydrochloride as an inhibitor or a competitive binding agent of the protein Mcl-1. Further provided is an application of doxorubicin hydrochloride as a drug for potential treatment of Parkinson's disease. Doxorubicin hydrochloride can act on the anti-apoptotic protein Mcl-1, and promote the separation of a pro-apoptotic protein bonded to the anti-apoptotic protein Mcl-1 by means of competitive binding of Mcl-1, thereby achieving the effect of inhibiting the anti-apoptotic protein. At the same time, the released pro-apoptotic protein can play a role in promoting apoptosis. IC50 of doxorubicin hydrochloride for Mcl-1 is 6.84 μM.
RISPERDAL CONSTA produced osteodystrophy in male and female rats in a 1-year toxicity study and a 2-year carcinogenicity study at a dose of 40 mg/kg administered IM every 2 weeks.

RISPERDAL CONSTA produced renal tubular tumors (adenoma, adenocarcinoma) and adrenomedullary pheochromocytomas in male rats in the 2-year carcinogenicity study at 40 mg/kg administered IM every 2 weeks. In addition, RISPERDAL CONSTA produced an increase in a marker of cellular proliferation in renal tissue in males in the 1-year toxicity study and in renal tumor-bearing males in the 2-year carcinogenicity study at 40 mg/kg administered IM every 2 weeks. (Cellular proliferation was not measured at the low dose or in females in either study.)

The effect dose for osteodystrophy and the tumor findings is 8 times the IM maximum recommended human dose (MRHD) (50 mg) on a mg/m 2 basis and is associated with a plasma exposure (AUC) 2 times the expected plasma exposure (AUC) at the IM MRHD. The no-effect dose for these findings was 5 mg/kg (equal to the IM MRHD on a mg/m 2 basis). Plasma exposure (AUC) at the no-effect dose was one third the expected plasma exposure (AUC) at the IM MRHD. 

Neither the renal or adrenal tumors, nor osteodystrophy, were seen in studies of orally administered risperidone. Osteodystrophy was not observed in dogs at doses up to 14 times (based on AUC) the IM MRHD in a 1-year toxicity study. 

The renal tubular and adrenomedullary tumors in male rats and other tumor findings are described in more detail in Section 13.1 (Carcinogenicity, Mutagenesis, Impairment of Fertility).

The relevance of these findings to human risk is unknown.
PROBLEM TO BE SOLVED: To obtain a diagnostic agent for diabetic symptomless kidney obstacle containing parathyroid hormones. SOLUTION: This diagnosis agent processes an ascending function of serum calcium and includes 10-400 units, especially 50-100 units, of parathyroid hormones or their salts comprising peptides or their salts bearing molecular weights of ca. 4,000-10,000 as an active ingredient. Preferably, a human- parathyroid hormone (1-34) bearing 34 amino acid sequence of the molecular weight of ca. 4,400 is illustrated and thyriparatide acetate is exemplified as the salt. This diagnostic agent is formulated in forms of injection, rectum absorbent, cutanous absorbent, oral administrating agent, etc. This agent diagnoses a kidney function having symptomless kidney obstacle, which is not yet diagnosed to be renal diabetes through it is diabetes, due to the rate of excretion below 15μm/min., and is useful for prevention against attack and advance.  The diagnosis is carried out by detecting a trace of albumin in urine by NAG increasing reaction in urine after administrating parathyroid hormones.
Dry weight will be adjusted at the start of the intervention period in all subjects in the intervention group with a normalized blood volume below 65 ml/kg, regardless the occurrence of intradialytic hypotension associated adverse events during the baseline period. Dry weight will be adjusted once with 0,5kg.
Cerebral intracranial aneurysms are common. In angiographic and autopsy studies, estimates for prevalence vary between 0.2 and 9.9 percent. The methods used to detect the aneurysms markedly influenced the proportion of aneurysms. Retrospective autopsy studies probably give an underestimation and prospective angiography studies an overestimation of the actual prevalence. Accurate data on the prevalence of intracranial aneurysms are essential in evaluating the results of screening programs for aneurysms in general population.

During the past decade, MRA, as a preferred accuracy modality for noninvasive intracranial vascular imaging at most centers, is playing an increasing role in the evaluation of patients suspected of having intracranial aneurysms. In recurrent study, we have tested that MRA at 3T has excellent sensitivity, accuracy, and correlation with DSA and is comparable to catheter cerebral angiography for the evaluation of patients with intracranial aneurysms (Stroke, in press). Therefore, we examined trends in intracranial aneurysm prevalence with the use of MRA at 3.0T to determine the true prevalence of cerebral intracranial aneurysms in the general middle-aged or elder population.
60 patients between 18-65 years of age with ASA I-II who were scheduled for laparoscopic cholecystectomy were included in the study. Patients with local anesthesia allergy, chronic use of analgesics, BMI\> 35 kg/m2, psychiatric disease, kidney and/or liver dysfunction, coagulopathy and pregnancy will not be included in the study. The patients who are taken to the operating room will be recorded their first data while standard monitorization is performed.

Propofol 2 mg/kg and fentanyl 1 mg/kg are injected for induction and rocuronium 0.5 mg/kg is injected for muscle relaxation. Patients with adequate muscle relaxation will be intubated with an appropriate endotracheal tube and mechanical ventilation will be initiated. Sevoflurane concentration appropriate for the maintenance of anesthesia will be given in air/O2 mixture at FiO2 with a flow rate of 2 lt / min. For intraoperative analgesia, remifentanil infusion of 0.2mcg / kg / min will be infused. During the operation, arterial pressure will be maintained within the limits of 20% of the initial measurement. The mechanical ventilation parameters will be arranged at the appropriate frequency and tidal volume that make EtCO t 30-40 mmHg. After removal of the gallbladder, Tramadol 1 mg/kg and Metaclopromide 2 mg/kg iv will be administered to all patients. At the end of the operation, a right-sided subcostal transabdominal plan block will be applied to the patients by ultrasound aided. While applying subcostal transabdominal plan block, %2,5 Marcaine 20 ml will be given between transverse and rectus abdominis muscle immediately next to the linea semilunaris in a group of patients. The other group of patients received %2,5 Marcaine 5 ml between the transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volumes lateral to this point near the subcostal margin. Patient-controlled analgesia devices with Tramadol will be prepared for postoperative analgesia. Rest and coughing pains, nausea and total PCA consumption will be recorded10 minutes, 30 minutes, 1, 3, 6, 24 hours postoperatively. Verbal Numerical Rating Scala (0 = no pain; 10 = the most severe pain you can imagine) for pain and Categorical Scoring Method (0 = none; 1 = less; 2 = too; 3 = too much) for nausea will be used. Complications such as infection, bleeding, and subcutaneous emphysema will be recorded.
With the progress of transplantation technology，allogeneic hematopoietic stem cell transplantation is becoming an important treatment for hematological diseases and the long-term survival of patients is gradually improved. However, thrombocytopenia after transplantation has always been an important complication. Studies have shown that about 20% patients had different degrees of thrombocytopenia. Eltrombopag could promote hematopoietic stem cell proliferation and differentiation in vitro studies. It has also been widely used in the treatment of immune thrombocytopenia (ITP) and aplastic anemia(AA) and increased platelet levels in such diseases. Eltrombopag is also used to treat poor platelet engraftment after transplantation and the effective rate is about 60%-80%. Therefore, the application of Eltrombopag at early time after transplantation might promote platelet engraftment and reduce platelet transfusions.
The study will involve a randomized, double blind, non-inferiority clinical trial with two treatment arms conducted in three academic institutions (the Centre for Addiction and Mental Health (CAMH) in Toronto, Ontario; the Ontario Shores Centre for Mental Health Sciences in Whitby, Ontario; and University of British Columbia (UBC) Hospital in Vancouver, British Columbia). The investigators are pursuing a non-inferiority clinical trial in an effort to compare MST to right unilateral ultrabrief pulse ECT (RUL-UB-ECT). Treatment will be administered two to three days per week. Depression symptoms will be assessed with the 24-item Hamilton Depression Rating Scale (HRSD-24) and suicidality will be assessed with the Scale for Suicidal Ideation (SSI). Remission will be defined as HRSD-24 \< or = 10 and a \> 60% decrease in scores from baseline on two consecutive ratings. Once a participant reaches remission, a second rating to confirm remission will be conducted immediately before their next scheduled treatment. If remission is confirmed, they will then be considered a completer of the acute treatment course. Remission of suicidal ideation is defined as a score of 0 on the SSI. Therefore, there will be no specific minimum number of treatments that patients must receive to be classified as remitters. However, patients who do not meet remission criteria after 21 treatment sessions will be considered non-remitters and will cease treatment sessions. This maximum treatment number was chosen allowing for the possibility that MST may require more treatment sessions to achieve remission, similar to RUL-UB ECT. The blind will not be broken to participants until the completion of the entire study.
The invention discloses a traditional Chinese medicine wash solution for curing dermatitis, vulvopathy and vaginitis. The traditional Chinese medicine comprises cnidium fruit 400 parts, alaum 400 parts, hibiscus skin 350 parts, broom cypress fruit 320 parts, hairy vein agrimony 300 parts, flavescent sophora root 280 parts, gentian grass 250 parts, argyi leaf 250 parts, light brown gentianae loureiri 240 parts, coptis 230 parts, phellodendron bark 200 parts, gallnut 200 parts, dittany bark 200 parts, atractylis ovata 180 parts, herba siegesbeckiae grass 180 parts, panicled swallowwort root 160parts, coralbean bark 150 parts, sulphur 100 parts, camphor 50 parts and baras camphor 50 parts using the weight part as the unit essentially. The traditional Chinese medicine wash solution of the invention is capable of eliminating dampness and heat, dispersing pathogenic wind and relieving itching. The invention is used for curing scabies, sores and ringworms, eczema, pruritus, itching of pudendum and the like which are caused by damp-heat afflux, further the invention is used for curing the illnesses of dermatitis, vulvopathy, vaginitis and the like. The prescription is simple, and the production is convenient. The traditional Chinese medicine wash solution of the invention is made by the pure Chinese herbal medicine, the curative effect is obvious, and the toxic and side effects are small with the simultaneous treatment of the cause and symptom, further the invention has no rebound after curing. The invention can be prepared into the spraying type and the suppository, the usage isconvenient, thereby the invention has an extensive application value.
The present invention provides compositions and methods for sensitizing a bacterium to an antibacterial the method comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance. Methods for killing an antibacterial-resistant bacterium comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance and exposing the bacterium to an antibacterial are also provided. The methods may also include the step of identifying the bacterium and the antibacterial resistance profile of the bacterium and tailoring the methods accordingly. Exemplary entry promoting agents provided are polyhexamethylene biguanide (PHMB) and polyhexamethyleneguanide (PHMG). Exemplary agents that inhibit antibacterial resistance are agents that bindto and inhibit antibacterial-resistance determinants such as beta-lactamases, PBP2a, NDM-1 and Vim2. Compositions, pharmaceutical compositions/formulations and medical uses thereof are also provided according to the invention.
The pacing self-management program (3 one-on-one sessions weekly for 3 consecutive weeks) focused on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), MS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
Methylin has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction [see Warnings and Precautions (5.1)]. Methylin can be diverted for non medical use into illicit channels or distribution.

Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of methylphenidate may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including Methylin, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses and or unapproved methods of administration, such as snorting or injection
[Problem] To provide: an emulsion composition that may contain an oily composition other than vegetable oils and may not necessarily contain xanthan gum and welan gum as essential components; a cosmetic composition; and a method for producing an emulsion composition. [Solution] This emulsion composition contains an oily component, an aqueous dispersion medium, an emulsifier, and a cellulose nanofiber. The cellulose nanofiber is an emulsion stabilizer and is obtained by defibrating unmodified cellulose. The blending amount of the emulsifier is less than 20% by mass of the total emulsion composition. This cosmetic composition contains the emulsion composition. This method for producing an emulsion composition comprises a step of adjusting an oil phase, a step of adjusting an aqueous phase, and an emulsification step of mixing the oil phase and the water phase. A cellulose nanofiber obtained by defibrating unmodified cellulose is added during the water phase adjustment step and/or the emulsification step. An emulsifier is added during at least one of the oil phase adjustment step, the water phase adjustment step, and the emulsification step.
EMFLAZA Oral Suspension contains benzyl alcohol and is not approved for use in pediatric patients less than 2 years of age. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol-preserved drugs, including EMFLAZA. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations.   
When prescribing EMFLAZA Oral Suspension, consider the combined daily metabolic load of benzyl alcohol from all sources, including EMFLAZA Oral Suspension (EMFLAZA Oral Suspension contains 10.45 mg of benzyl alcohol per mL; EMFLAZA Tablets do not contain benzyl alcohol) and other drugs containing benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known. At the recommended dose of 0.9 mg/kg/day of EMFLAZA Oral Suspension, patients would receive approximately 0.4 mg/kg/day of benzyl alcohol [see Use in Specific Populations (8.4)].
This protocol is designed to assess the safety and efficacy of TG-C in treating symptoms of osteoarthritis of the knee and determining disease modifying effects of TG-C. This study is intended for the treatment of patients with KL Grade 2 and 3 osteoarthritis and OARSI JSN Grade 1 and 2. Assessments will be made on both the symptomatic effects of pain (VAS), function (WOMAC), and Quality of Life (SF-12) as well as the physical effects (JSW, MRI evaluations of whole knee joint organ tissues and structure) and biochemical biomarkers. This is a placebo-controlled study, TG-C will be compared to normal saline as a control. Additionally, this protocol is designed to evaluate the safety of TG-C. Safety will be evaluated by observation of the injection site for irritation or other effects, the incidence and severity of adverse events, and changes in physical examination findings, radiographic criteria, and laboratory tests. Patients will be followed for 24 months for both safety and efficacy with annual cancer surveillance questionnaires through 15 years post dosing for subjects who do not enroll in the Long Term Safety study.
Participants will also receive a 60-minute session of motivational interviewing via videoconference or telephone (at participant discretion) in their home from a trained nurse and text messages from a nurse for 6 weeks, as described in arm 1. In addition, patients will receive daily text messages from their significant other for 6 weeks. Researchers developed the 42 significant other text messages. The motivational interviewing nurse will provide the text messages to the significant other in writing. The order of texts sent from the significant other will be randomized so that we can determine their effectiveness in general. The significant other will be asked to type and send the text message listed for each date to the patient. Study staff will confirm by phone that the patient received the first text from the significant other. Patients will be asked to track the number of text messages from the significant other that they read over the 6-week period using the log provided.
During a regular session, patients with gait impairment will work on gait with the following tasks for 30min: weights on ankles, dual tasks, UE support, partial body weight support, speed challenges, obstacles, and head turning. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
The invention discloses a medical data sharing and publishing method, a system, equipment and a medium, which comprise the following steps: the medical institution registers with the CA server to qualify as a legitimate member node of the federation blockchain. The medical institution establishes a medical database to store medical data. During the medical data sharing process: the requestor needs to pay rewards to the participants to motivate more medical institutions to participate in medical data sharing. The participant will process the raw medical data by using the KPrivBayes algorithm. The requester and the participant interact by invoking a smart contract that has been deployed on the federated blockchain, and medical data sharing transactions generated by the smart contract are recorded and permanently saved. The medical data release process is completed through data interaction between the data release server and the medical data release platform. The invention has the advantages that: medical data can be shared and released efficiently, and data privacy disclosure can be avoided. Overcomes the defect that the prior medical system can not provide effective privacy protection.
The present invention relates to a homogeneous polysaccharide with an immunoregulation activity and a preparation method thereof. The homogeneous polysaccharide with the immunoregulation activity is a single chromatographic peak and has a molecular weight of 6880 ±50 Da and an optical rotation value of 158.4±0.5°. An infrared spectrum has an α-configuration sugar characteristic absorption peak at 847.6 cm -1 . Hydrogen-proton characteristic chemical shifts in hydrogen spectra of the polysaccharide are δ 5.40, 3.95, 3.84 and 3.61. Carbon signal characteristic chemical shifts in carbon spectra are δ 99.6, 76.6, 73.3, 71.5, 71.1 and 60.4. The homogeneous polysaccharide has an effect of enhancing body immunity, can achieve excellent anti-tumor, antiviral and anti-infection effects and the like in regulation of immunity-related diseases, and has potential development values in drug and health care product industries for treatment and prevention of the diseases.
Patients receive fulvestrant IM on day 1 (days -14, 1, and 15 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm C.
Phase 2: This phase will adopt competitive enrollment, and the Bayesian prediction probability method will be used to monitor the main efficacy index of the trial ORR in real time to determine the early termination or continue the trial. A maximum number of 57 patients were enrolled in this stage.